HIV-1 treatment as prevention: the good, the bad, and the challenges.
HIV-1 treatment as prevention: the good, the bad, and the challenges.
复制标题
DOI：
10.1097/coh.0b013e32834788e7
复制
发表时间：
2011-07
影响因子：
4.1
通讯作者：
Cohen MS
中科院分区：
文献类型：
--
作者：
Smith K;Powers KA;Kashuba AD;Cohen MS
这项工作的重点是使用抗逆转录病毒药物预防艾滋病毒1型的性传播。两项随机临床试验表明，在接触HIV-1之前提供的抗逆转录病毒药物提供了实质性的保护，表面上与生殖器分泌物中抗逆转录病毒治疗（ART）的浓度成正比。对使用艾滋病毒治疗作为预防的强烈关注导致了建模练习，生态学研究和观察性研究的出版，其中大部分支持ART的潜在益处。然而，成功使用ART预防的后勤要求是相当大的。抗逆转录病毒疗法将成为艾滋病毒-1综合预防的基石。持续的研究将是至关重要的，以衡量预期的好处，并发现实施障碍和不利的后果，这样一个计划，特别是增加原发性抗逆转录病毒药物耐药。
This work focuses on the use of antiretroviral agents to prevent the sexual transmission of HIV-1. Two randomized clinical trials demonstrated that antiretroviral agents provided before exposure to HIV-1 offer substantial protection, ostensibly directly proportional to the concentration of antiretroviral therapy (ART) in the genital secretions. Intense focus on the use of HIV treatment as prevention has led to publication of modeling exercises, ecological studies, and observational studies, most of which support the potential benefits of ART. However, the logistical requirements for successful use of ART for prevention are considerable. ART will serve as a cornerstone of combination prevention of HIV-1. Continued research will be essential to measure anticipated benefits and to detect implementation barriers and untoward consequences of such a program, especially increases in primary ART resistance.